Th serotonin hypothesis of pulmonary hypertension revisited

Margaret R MacLean, Yvonne Dempsie

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)


The serotonin hypothesis of pulmonary arterial hypertension (PAH) arose after an outbreak of PAH in patients taking the anorexigenic drugs aminorex and dexfenfluramine. Both of these drugs are serotonin transporter (SERT) substrates and indirect serotinergic agonists. There is now a wealth of evidence to support a role for serotonin in the pathobiology of PAH. Synthesis of serotonin can occur in pulmonary artery endothelial cells by the enzyme tryptophan hydroxylase 1 (TPH1). Serotonin then acts at the 5-HT(1B) receptor and the SERT to mediate constriction and proliferation of pulmonary artery smooth muscle cells. Downstream signalling molecules which play a role in serotonin-induced constriction and proliferation include reactive oxygen species (ROS), Rho-kinase (ROCK) p38 and extracellular signal-regulated kinase (ERK). There is also evidence to suggest that serotonin may interact with the bone morphogenetic receptor type II (BMPRII) to provide a 'second hit' risk factor for PAH.
Original languageEnglish
Pages (from-to)309-22
Number of pages14
JournalAdvances in Experimental Medicine and Biology
Publication statusPublished - 2010


  • pulmonary arterial hypertension
  • serotonin
  • endothelial cells


Dive into the research topics of 'Th serotonin hypothesis of pulmonary hypertension revisited'. Together they form a unique fingerprint.

Cite this